Placebo for Niraparib clinical trials

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.